We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+2.42%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$940M
AUM Growth
-$233M
(-20%)
Cap. Flow
-$192M
Cap. Flow
% of AUM
-20.48%
Top 10 Holdings %
Top 10 Hldgs %
46.78%
Holding
113
New
30
Increased
18
Reduced
25
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$26.6M |
| 2 |
Elevance Health
ELV
|
+$26.1M |
| 3 |
Mineralys Therapeutics
MLYS
|
+$16.4M |
| 4 |
Baxter International
BAX
|
+$16.3M |
| 5 |
RadNet
RDNT
|
+$14.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$30.3M |
| 2 |
Cardinal Health
CAH
|
+$29.6M |
| 3 |
Eli Lilly
LLY
|
+$29.3M |
| 4 |
Intuitive Surgical
ISRG
|
+$20.9M |
| 5 |
Merck
MRK
|
+$19.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Insulet
PODD
$9.94B
| – | – |
-20,000
| Closed | -$5.22M |
|
102
QuidelOrtho
QDEL
$1.01B
| – | – |
-150,000
| Closed | -$6.68M |
|
103
Rhythm Pharmaceuticals
RYTM
$8B
| – | – |
-150,000
| Closed | -$8.4M |
|
|
SLN
104
Silence Therapeutics
SLN
$672M
| – | – |
-200,000
| Closed | -$1.38M |
|
105
STAAR Surgical
STAA
$1.26B
| – | – |
-100,000
| Closed | -$2.43M |
|
|
SWTX
106
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-100,000
| Closed | -$3.61M |
|
107
TG Therapeutics
TGTX
$7.64B
| – | – |
-150,000
| Closed | -$4.51M |
|
108
Travere Therapeutics
TVTX
$5.83B
| – | – |
-100,000
| Closed | -$1.74M |
|
109
Viking Therapeutics
VKTX
$4.02B
| – | – |
-150,000
| Closed | -$4.74M |
|
|
WBA
110
DELISTED
Walgreens Boots Alliance
WBA
| – | – |
-500,000
| Closed | -$4.67M |
|
111
Zentalis Pharmaceuticals
ZNTL
$297M
| – | – |
-1,050,000
| Closed | -$3.18M |
|
112
Kyverna Therapeutics
KYTX
$503M
| – | – |
-350,000
| Closed | -$1.31M |
|
|
NARI
113
DELISTED
Inari Medical, Inc. Common Stock
NARI
| – | – |
-350,000
| Closed | -$17.9M |
|
Similar funds
CL
ACM
ACG
NSUP
TP
ACP
TA
AG
Integral Health Asset Management's Q1 2025 Portfolio in Review
As of Q1 2025, Integral Health Asset Management held 113 positions worth $940M, down 20% from $1.17B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Integral Health Asset Management withdrew a net $192M in Q1 2025, closing 32 positions and reducing 25 holdings. Its most notable exit was Centene, an estimated $30.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier.
Against the trend, Integral Health Asset Management opened a new position in Novartis worth $27.9M.
- Integral Health Asset Management's largest Q1 2025 buy was Novartis: 250,000 shares worth $27.9M.
- Integral Health Asset Management added most to Mineralys Therapeutics in Q1 2025, an estimated $16.4M increase.
- Integral Health Asset Management's biggest Q1 2025 reduction was CVS Health, cutting an estimated $18M.
- Integral Health Asset Management fully exited Centene in Q1 2025, selling an estimated $30.3M.
- Integral Health Asset Management's ten largest holdings make up 47% of its $940M portfolio in Q1 2025.
- Integral Health Asset Management opened 30 new positions and closed 32 in Q1 2025.
- Integral Health Asset Management's portfolio value fell 20% quarter-over-quarter to $940M.
Based on Integral Health Asset Management's 13F filing for Q1 2025, filed 15 May 2025.